Name: CJC without DAC
SKU: 390
Availability: InStock

CJC-1295 (without DAC)

Scientific Overview, Mechanism, Clinical Use and Evidence

Scientific Overview

CJC-1295 (without DAC) is a synthetic analog of growth hormone–releasing hormone (GHRH 1–29) designed to stimulate endogenous growth hormone (GH) secretion. Unlike the DAC-modified version, CJC-1295 without DAC has a shorter half-life and is intended to more closely mimic physiologic, pulsatile GH release when administered intermittently.

Mechanism of Action

CJC-1295 without DAC binds to the GHRH receptor on pituitary somatotrophs, increasing cyclic AMP signaling and stimulating GH synthesis and release. Because it lacks drug affinity complex (DAC) modification, its activity is shorter in duration, favoring pulsatile GH secretion patterns:

• Stimulates physiologic pulsatile GH release
• Increases downstream IGF-1 production
• Supports body composition and tissue repair
• Favors short-acting GH secretion aligned with normal physiology

Biological and Clinical Effects

Human studies of GHRH analogs demonstrate increases in GH and downstream IGF-1, with effects on body composition, nitrogen balance, and tissue repair. Short-acting GHRH analogs are often discussed for their ability to support physiologic GH rhythms rather than sustained hormone elevation.

Time of Use / Treatment Duration

Clinical practice protocols commonly describe cycles of 8–12 weeks, followed by reassessment of clinical response and laboratory markers such as IGF-1. Longer-term use has been discussed but lacks robust long-term safety data from controlled trials.

Safety, Tolerability, and Precautions

CJC-1295 without DAC is generally reported as well tolerated in clinical research. Possible adverse effects include transient flushing, headache, injection-site reactions, and mild water retention. Precautionary exclusions typically include pregnancy, lactation, active malignancy, and uncontrolled endocrine disease.

Detailed References

Teichman SL et al. (2006). Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805.

Veldhuis JD et al. (2005). Endocrine control of pulsatile growth hormone secretion. Endocrine Reviews, 26(5), 594–624.

Thorner MO et al. (1995). Physiologic regulation of growth hormone secretion. Endocrine Reviews, 16(1), 22–38.

LaValle J. (2022). The Complete Guide to Peptides. Clinical perspectives on GHRH analogs and hormone optimization.

Posology (Clinical Practice–Oriented)

Commonly discussed dosing ranges for CJC-1295 without DAC are 100–300 mcg per injection, administered subcutaneously 1–3 times daily.

Dosing is typically timed to periods of low insulin (e.g., fasting states) to support physiologic GH release.

Use must be individualized by the prescribing physician.

Clinical Practice Framing

In scientific-medical and integrative medicine contexts, CJC-1295 without DAC is positioned as a physiologic GH secretagogue rather than hormone replacement. Functional medicine literature emphasizes conservative dosing, patient selection, and objective monitoring when using GHRH analogs.

The peptides described in this material are intended strictly for research purposes only. They are not approved for human or veterinary use, clinical application, diagnosis, treatment, or prevention of any disease.

Any research involving these compounds must be conducted in compliance with applicable laws and regulations in the country where the research is performed, including prior approval by a duly constituted Ethics Committee or Institutional Review Board (IRB), where required.

RegenPept acts solely as a supplier of research-grade materials and assumes no responsibility or liability for the design, conduct, regulatory compliance, interpretation, or outcomes of any research involving these products.

Any dosage, administration protocols, or related information contained in this material are derived from publicly available scientific literature and are provided strictly for informational purposes. Such information does not constitute medical advice, therapeutic recommendation, or endorsement of any specific use by RegenPept.